Answers are grounded in this paper and cite their sources.
Cell-free expression (CFE) is an acellular biomanufacturing platform capable of producing diverse biomolecules, including proteins, enzymes, and mRNA, outside of living cells. Unlike traditional bioproduction, which requires sterile culture systems and large-scale bioreactors, CFE enables rapid, modular, and decentralized synthesis. CFE extracts can be freeze-dried, stored for extended periods, and reactivated on demand by simply adding a nucleic acid template. This makes it particularly suited for point-of-need applications such as diagnostics, vaccines, and potentially therapeutics in remote, resource-limited, or emergency settings. However, the same features introduce novel biosecurity concerns. Commercially available CFE kits already support the production of bacteriophages and virus-like particles with minimal specialized equipment. As benchtop DNA synthesis and CFE technologies become increasingly accessible, barriers of skill, facilities, and resources are significantly reduced, enabling malicious actors or small autonomous groups to generate harmful biological agents. To address these risks while enabling safe deployment, we recommend: (1) investing in yield optimization and the development of modular, good manufacturing practice-compatible CFE units for distributed manufacturing (performance and scalability); (2) engineering CFE systems with bioorthogonal or otherwise nontransferable components to reduce potential misuse (intrinsic safety feature); and (3) implementing risk-based restrictions for different CFE formulations, balancing innovation with security oversight (tiered access controls). By combining these measures, CFE can be responsibly integrated into global health security infrastructure, delivering its transformative benefits without compromising biosecurity.
No takes yet. Share an insight, caveat, or question.
Chitayat et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: